PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Vascular BioSciences

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Vascular BioSciences Extends Patent Portfolio - Signs Exclusive IP License Agreement - Vascular BioSciences announced today that it has secured a worldwide exclusive license to intellectual property from Burnham Institute for Medical Research relating to work done by Erkki Ruoslahti M.D Ph.D., and Masanobu Komatsu, Ph.D
Vascular BioSciences Extends Patent Portfolio - Signs Exclusive IP License Agreement

 

NewswireToday - /newswire/ - San Diego, CA, United States, 2007/03/01 - Vascular BioSciences announced today that it has secured a worldwide exclusive license to intellectual property from Burnham Institute for Medical Research relating to work done by Erkki Ruoslahti M.D Ph.D., and Masanobu Komatsu, Ph.D.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Medical Research relating to work done by Erkki Ruoslahti M.D., Ph.D., and Masanobu Komatsu, Ph.D. on their discovery of the role of the intracellular protein R-Ras in neointimal hyperplasia, angiogenesis and vascular proliferation. R-Ras is a small GTPase of the Ras family that regulates cell survival and integrin activity. Drs. Komatsu and Ruoslahti found that R-Ras exerts a strong inhibitory effect on mitotic and invasive activities of activated endothelial cells and vascular smooth muscle cells, and promotes quiescence of these cells.

The discovery of this unexpected role for R-Ras in blood vessel homeostasis will enable Vascular BioSciences to target R-Ras signaling for therapeutic intervention in a wide range of disorders characterized by pathological vascular remodeling, vascular cell proliferation and endothelial activation. Such diseases include atherosclerosis, sepsis, systemic and pulmonary hypertension, diabetic vasculopathies, acute respiratory distress syndrome, post-angioplasty restenosis, collagen vascular diseases and other conditions. The ability of R-Ras to promote vascular quiescence may also be useful in anti-angiogenesis therapies for cancer and the engineering of mature blood vessels.

David Mann, CEO and Chairman of Vascular BioSciences commented, “This license agreement
with the Burnham Institute for Medical Research represents an extremely important expansion to our existing intellectual property portfolio and product pipeline. In addition to securing this valuable worldwide exclusive license, we gain the ability to work closely with internationally renowned scientists like Drs. Komatsu and Ruoslahti to develop novel innovative treatments for vascular diseases.”

Dr. Erkki Ruoslahti, Distinguished Professor and former President of Burnham Institute for Medical Research commented, “I believe that R-Ras opens up some entirely new possibilities for the treatment of vascular diseases and look forward to working with Vascular BioSciences on further development of this technology.”

About Vascular BioSciences & VBS Pharmaceuticals

Vascular BioSciences (vascularbiosciences.com), a diversified biomedical company based in San Diego, California, provides solutions for vascular-based diseases in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides diagnostic services, and advances therapies in order to improve outcomes for vascular-based disease patients.

A newly formed majority-owned subsidiary, VBS Pharmaceuticals, has been created to provide a framework for Vascular Biosciences to engage in drug discovery and pharmaceutical development targeting vascular-based diseases.

About Burnham Institute for Medical Research

Burnham Institute for Medical Research conducts world-class collaborative research dedicated to finding cures for human disease, improving quality of life, and thus creating a legacy for its employees, partners, donors, and community. The La Jolla, CA campus was established as a nonprofit public benefit corporation in 1976 and is now home to three major centers: the National Cancer Institute-designated Cancer Center, the Del E. Webb Center for Neurosciences and Aging, and the Infectious and Inflammatory Disease Center.
Burnham today employs over 750 people and ranks consistently among the world’s top 20 research institutes. In 2006, Burnham established a presence at the University of California, Santa Barbara, led by Dr. Erkki Ruoslahti, Distinguished Professor. Burnham is also establishing a campus at Lake Nona in Orlando, Florida that will focus on diabetes and obesity research and expand the Institute’s drug discovery capabilities.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Vascular BioSciences

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Vascular BioSciences Extends Patent Portfolio - Signs Exclusive IP License Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: David Mann - VascularBioSciences.com 
858-273-2744 dmann[.]vascularbiosciences.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Vascular BioSciences securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Vascular BioSciences / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  MagLar, Inc.

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)